May 3, 2024
by Andrii Buvailo
Biopharma insight
The advent of artificial intelligence (AI) in healthcare has catalyzed an epoch of change, reshaping diagnostic procedures, therapeutic strategies, and …
May 3, 2024
by Travis McCready
Biopharma insight
Artificial intelligence (AI) is one of the most disruptive technologies the Life Sciences sector has ever seen. It’s having a …
April 29, 2024
by Louise von Stechow
Biopharma insight
Drug development for rare (also referred to as orphan) diseases is notoriously challenging. Legislative initiatives, such as the 1983 US …
April 29, 2024
by Dr. Alexander Jarasch
Biopharma insight
Data in Life Sciences expert Dr Alexander Jarasch on a new wave of advanced data handling techniques that point the …
April 21, 2024
Biopharma insight
We have recently launched a report, “It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?” where …
April 17, 2024
by Viraj Mehta
Biopharma insight
Report highlights: We are currently at an exciting juncture where several big pharmaceutical companies have started adopting such models and …
April 9, 2024
by Bohdana Sokolova
Biopharma insight
The world of clinical trials is undergoing an evolution as the rise of decentralized clinical trials (DCTs) brings about a change …
April 8, 2024
by Andrii Buvailo
Biopharma insight
Sponsored by Lantern Pharma
Clinical trials are the lifeline of modern medicine, bridging the gap between lab-borne scientific discoveries and the availability of life-saving …
April 7, 2024
by Andrii Buvailo, PhD
Biopharma insight
In a detailed interview, Dr. Brian Jamieson, founder and CTO of Diagnostic Biochips (DBC), delves into the evolving landscape of …
March 25, 2024
by Andrii Buvailo, PhD
Biopharma insight
The biotech industry is experiencing a big wave of investment, similar to the high levels seen between 2020 and 2021. …
March 19, 2024
by Andrii Buvailo, PhD
Biopharma insight
NVIDIA's CEO, Jensen Huang, recently outlined the company's expanded focus on software solutions designed to facilitate the adoption of artificial …
March 18, 2024
by Irina Bilous
Biopharma insight
Historically, the approval rate for medicines treating central nervous system (CNS) disorders was low. By 2022, the success rate for …